Cemiplimab

Cemiplimab (trade name Libtayo) is a monoclonal antibody drug for the treatment of squamous cell skin cancer,[1] myeloma,[2] and lung cancer.[3]

Cemiplimab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetPD-1
Clinical data
Trade namesLibtayo
Other namesREGN-2810, cemiplimab-rwlc
AHFS/Drugs.comMonograph
MedlinePlusa618054
Pregnancy
category
  • US: N (Not classified yet)
    Routes of
    administration    		Intravenous
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Elimination half-life19 days
    Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    KEGG
    Chemical and physical data
    FormulaC6380H9808N1688O2000S44
    Molar mass143569.10 g·mol−1

    In Sept 2018 it was approved by the US FDA for treating "patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation".[4]

    Mechanism of action

    It targets PD-1 so it acts as a checkpoint inhibitor.[5]

    References
    1. H. Spreitzer (2 January 2018). "Neue Wirkstoffe: Cemiplimab". Österreichische Apothekerzeitung (in German) (1/2018).
    2. Clinical trial number NCT03194867 for "Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients" at ClinicalTrials.gov
    3. Clinical trial number NCT03430063 for "A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer" at ClinicalTrials.gov
    4. FDA approves first treatment for advanced form of the second most common skin cancer 28 Sept 2018
    5. New PD-1 Inhibitor OK'd for Cutaneous SCC - Sixth PD-1/PD-L1 checkpoint inhibitor approved by agency 2018
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.